HBVpol502, HBV polymerase (502 – 510)

TECHNICAL SPECIFICATIONS

1.MECHANISM OF ACTION

his peptide functions as a specific antigenic determinant for CD8+ cytotoxic T lymphocytes (CTLs). During active HBV replication within hepatocytes, the viral polymerase protein is processed via the proteasome into short peptides. The HBVpol502 epitope is transported into the endoplasmic reticulum, loaded onto HLA-A0201 molecules, and displayed on the surface of infected cells. As an exogenous synthetic peptide, it can be used to load the same HLA-A0201 molecules on antigen-presenting cells (APCs) in vitro.

2.PRODUCT INDICATIONS

• HBV-Specific T-Cell Immunology: Studying the frequency, phenotype (e.g., memory, exhausted), and functional quality (cytokine production, cytotoxicity) of HBV polymerase-specific CD8+ T cells in patients with acute, chronic, or resolved HBV infection.

• Immune Monitoring Assays: Serving as the stimulating antigen in standardized assays to detect and quantify HBV-specific CTL responses, including interferon-gamma ELISPOT, intracellular cytokine staining (ICS) by flow cytometry, and HLA tetramer staining.

• Therapeutic Vaccine Research: Evaluating the immunogenicity and efficacy of this epitope as a component in peptide-based, dendritic cell-based, or viral-vectored therapeutic vaccine strategies aimed at restoring functional T-cell responses in chronic HBV infection.

• Immune Escape & Viral Evolution Studies: Investigating the impact of polymerase gene mutations (commonly induced by nucleos(t)ide analog therapy) within this epitope on T-cell recognition, contributing to viral persistence and drug resistance.

3.CLINICAL EFFICACY OF PRODUCT

• Research & Diagnostic Tool Efficacy: It is highly effective in detecting and characterizing HBV-specific CTL responses in HLA-A*0201+ individuals, providing critical data on immune competence and viral control.

• Correlate of Viral Control: Strong and sustained CTL responses against polymerase epitopes, including HBVpol502, are associated with viral clearance in acute HBV infection and with lower viral load in chronic carriers. Its presence indicates a functional antiviral immune response.

• Therapeutic Vaccine Target: This epitope is a prime candidate component in investigational therapeutic vaccines for chronic hepatitis B. Such vaccines aim to break immune tolerance and induce de novo or boost existing CTL responses to achieve functional cure (HBsAg loss). Clinical trials have incorporated polymerase epitopes.

• Immune Monitoring in Therapy: Assays using this peptide are used in clinical research to monitor changes in virus-specific T-cell responses during antiviral therapy (with nucleos(t)ide analogs or interferon) or novel immunotherapies, serving as a biomarker for treatment-induced immune reconstitution.




4.DELIVERY & SHIPPING


We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods 
Main Method: International Air Freight


We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.